All publications

Export 167 results:
[ Author(Desc)] Title Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
P
Pillay D, Dunn DT.  2009.  The biology, epidemiology and clinical implications of transmitted HIV drug resistant viruses. 16th Conference on Retroviruses and Opportunistic Infections, February 2009.
Pillay D, Green H, UK HIV Drug Resistance Database.  2003.  The UK HIV Drug Resistance Database: development and use for national surveillance. 12th International HIV Drug Resistance Workshop, 10-14 June 2003.
Pillay D, Green H, Matthias R, Dunn DT, Phillips AN, Sabin CA, Evans B..  2005.  Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom. J Infect Dis. 192:967-73.
Pillay D, Green H, Gazzard B, Pozniak A, Matthias R, Johnson M, Churchill D, Fisher M, Hill T, Geretti AM et al..  2004.  Estimating resistance in drug experienced patients in the UK. 13th International Drug Resistance Workshop, 8-12 June 2004.
Pond S.LKosakov, Posada D., Stawiski E., Chappey C., Poon A.F, Hughes GJ, Fearnhill E, Gravenor M.B, Leigh Brown A, Frost S.D.  2009.  An evolutionary model-based algorithm for accurate phylogenetic breakpoint mapping and subtype prediction in HIV-1. PLoS Comput Biol. 5:e1000581.
Price H., Dunn DT, Asboe D, Pozniak A, Gazzard B, Pillay D, UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study.  2009.  Positive and negative drug selection pressures on the N348I connection domain mutation; new insights from in vivo data. 18th International HIV Drug Resistance Workshop, June 2009.
Price H., Asboe D, Pozniak A, Gazzard B, Fearnhill E, Pillay D, Dunn DT.  2010.  Positive and negative drug selection pressures on the N348I connection domain mutation: new insights from in vivo data. Antivir Ther. 15:203-11.
Prosperi M.C, Mackie N, Di Giambenedetto S., Zazzi M, Camacho R., Fanti I., Torti C., Sonnerborg A., Kaiser R., Codoner F.M et al..  2011.  Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. J Antimicrob Chemother. 66:1886-96.
R
Ragonnet-Cronin M, Hue S, Tostevin A, Pozniak A, Fawcett T, Brown A, Dunn DT, Leigh Brown A.  2017.  Nondisclosed MSM link together in HIV transmission networks. CROI.
Ragonnet-Cronin M, Shilaih M, Günthard HF, Hodcroft E, Boni J, Fearnhill E, Dunn DT, Yerly S, Klimait T, Aubert V et al..  2016.  A Direct Comparison of Two Densely Sampled HIV Epidemics: The UK and Switzerland. Sci Rep. 6
Ragonnet-Cronin M, Hue S, Tostevin A, Pozniak A, Fawcett T, Brown A, Dunn DT, Leigh Brown A.  2017.  Nondisclosed MSM link together in HIV transmission networks. 24th International HIV Dynamics and Evolution.
Ragonnet-Cronin M, Lycett S, Hodcroft E, Hue S, Fearnhill E, Dunn DT, Delpech V, Leigh Brown A, UK Collaborative Group on HIV Drug Resistance.  2013.  Dynamics of Non-B HIV Transmission in the UK. 20th Conference on Retroviruses and Opportunistic Infections, 3-6 March 2013.
Ragonnet-Cronin M, Lycett S, Hodcroft E, Hue S, Fearnhill E, Brown A, Delpech V, Dunn DT, Leigh Brown A.  2016.  Transmission of Non-B HIV Subtypes in the United Kingdom Is Increasingly Driven by Large Non-Heterosexual Transmission Clusters. J Infect Dis. 213:1410-8.
Ragonnet-Cronin M, Hué S, Hodcroft EB, Tostevin A, Dunn D, Fawcett T, Pozniak A, Brown AE, Delpech V, Brown AJLeigh.  2018.  Non-disclosed men who have sex with men in UK HIV transmission networks: phylogenetic analysis of surveillance data.. Lancet HIV. 5(6):e309-e316.
Ragonnet-Cronin M, Lycett S, Hodcroft E, Hue S, Fearnhill E, Dunn DT, Delpech V, Leigh Brown A.  2013.  Non-B HIV transmission networks in the UK. 20th International HIV Dynamics & Evolution Conference, 8-11 May 2013.
Ragonnet-Cronin M, Lycett S, Hodcroft E, Hue S, Fearnhill E, Dunn DT, Delpech V, Leigh Brown A.  2012.  Automated Analysis of A1 cluster dynamics in the UK 2007-2010. 19th International HIV Dynamics & Evolution Conference, 25-28 April 2012.
Ragonnet-Cronin M, Hodcroft E, Hue S, Fearnhill E, Delpech V, Leigh Brown A, Lycett S.  2013.  Automated analysis of phylogenetic clusters. BMC Bioinformatics. 14:317.
S
Santoro MM, Silberstein FC, Forbici F., Bansi L, Dunn DT, Fearnhill E, Boumis E, Narciso P, Antinori AM, Palamara G et al..  2011.  Different drug-resistance development in HIV-1 infected patients failing a first-line antiretroviral therapy containing NNRTIs. IAS, 17-20 July 2011.
Santoro MM, Sabin CA, Forbici F., Bansi L, Dunn DT, Fearnhill E, Boumis E, Nicastri E., Antinori AM, Palamara G et al..  2013.  Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues. HIV Med. 14:571-7.
Schultze A, Paredes R, Sabin CA, Phillips AN, Pillay D, Mackie N, Castagna A, Chadwick D, Falconer K, Geretti AM et al..  2017.  The association between detected drug resistance mutations and CD4+ T-cell decline in HIV-positive individuals maintained on a failing treatment regimen.. Antivir Ther.